Skip to main content
. Author manuscript; available in PMC: 2025 Aug 3.
Published in final edited form as: Cancer Immunol Res. 2025 Feb 3;13(2):210–228. doi: 10.1158/2326-6066.CIR-23-1011

Figure 6 |. Single cell RNA sequencing of CAR T cells in 3D co-cultures with PDOTS.

Figure 6 |

A, Schematic of conditions for baseline (0 hr) and 24 hr of PDOTS +/− B7-H3.CAR-T cells in 3D culture with indicated treatment conditions. B-C, Uniform Manifold Approximation and Projection (UMAP) of all tumor and immune cells (77,284 cells) from the conditions indicated (B) with 9 unique populations identified (C). D, Bar plots of proportional changes in unique tumor and immune cell clusters identified in C. E-F, UMAP of 28,227 cells from the conditions indicated (E) and 10 unique populations identified (F) among sub-clustered CAR-T cells. G-H, UMAP of 15,179 cells from the conditions indicated (G) and 5 unique populations identified (H) among sub-clustered cancer cells. I, Bar plots of proportional changes in unique tumor cell clusters identified in H. J, Dot plot for select genes differentially expressed in the 5 sub-clusters of cancer cells. K, tracks plots depicting the changes in B7-H3 (CD276) gene expression across the different cancer cell sub-clusters at baseline (0 hr) and after 24 hr +/− B7-H3.CAR-T cell challenge with/without TBK1i (1 μM), αPD-1 (pembrolizumab, 250 μg/mL), or PD-1 plus TBK1i.